8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2019 / Interventional exercise training trial
Researchers evaluated the effects of 12 weeks of aerobic and resistance exercise training on NAD+ salvage pathway enzymes in young and older individuals, alongside a separate cohort testing 6 weeks of high-intensity interval training on adipose tissue. Baseline skeletal muscle NAMPT correlated negatively with age (r2 = 0.297, P < 0.001, n = 57), with VO2 peak being the best predictor. Aerobic training increased muscle NAMPT abundance by 12% in young and 28% in older individuals, while resistance training increased it by 25% in young and 30% in older individuals; other enzymes (NRK2, NMNAT1, NMNAT3) did not change. In abdominal subcutaneous adipose tissue, NAMPT, NRK1, and NMNAT1/2 levels were unaffected by age or 6 weeks of interval training.
de Guia RM, Agerholm M, Nielsen TS, et al. Physiol Rep, 2019. PMID 31207144
2019 / Placebo-controlled, randomized, double-blind, crossover trial
In a randomized, double-blind, placebo-controlled crossover study, 12 aged men received 1 g per day of oral nicotinamide riboside (NR) or placebo for 21 days. Targeted metabolomics demonstrated that NR increased the muscle NAD+ metabolome, as shown by higher nicotinic acid adenine dinucleotide and nicotinamide clearance products. Muscle RNA sequencing showed downregulation of energy metabolism and mitochondrial pathways, though mitochondrial bioenergetics were not altered. Additionally, NR supplementation reduced circulating inflammatory cytokine levels.
Elhassan YS, Kluckova K, Fletcher RS, et al. Cell Rep, 2019. PMID 31412242
2019 / Double-blind, placebo-controlled randomized trial
A double-blind, placebo-controlled trial evaluated the effect of daily oral Lactobacillus casei Shirota (LcS) for 3 months in senior patients with distal radius fracture. Out of 293 enrolled, 264 eligible patients were randomized to receive oral placebo or LcS. Over the 3-month intervention period, Michigan Hand Questionnaire (MHQ) scores, radial deviation and inclination, and ulnar deviation and variance showed a significantly faster improvement in patients taking LcS compared to placebo.
Zhang C, Xue S, Wang Y, et al. J Orthop Surg Res, 2019. PMID 31412879
2019 / Randomized, double-blind, placebo-controlled parallel-group comparative study
A randomized, double-blind, placebo-controlled parallel-group comparative study evaluated the effect of Hericium erinaceus fruiting body supplements taken for 12 weeks on cognitive functions. Cognitive performance was assessed using the Mini Mental State Examination (MMSE), Benton visual retention test, and Standard verbal paired-associate learning test (S-PA). MMSE alone showed that oral intake of H. erinaceus significantly improved cognitive functions and prevented deterioration.
Saitsu Y, Nishide A, Kikushima K, et al. Biomed Res, 2019. PMID 31413233
2019 / Randomized, double-blind, placebo-controlled multicenter trial
In the MASTERS trial, healthy adults aged 65 and older performed 14 weeks of supervised progressive resistance training (PRT) while receiving either 1,700 mg/day metformin (N = 46) or placebo (N = 48). Placebo gained more lean body mass (p = .003) and thigh muscle mass (p < .001) than metformin. Increases in thigh muscle area (p = .005) and density (p = .020) were also greater in placebo compared with metformin, alongside a non-statistically significant trend for blunted strength gains in the metformin group. Metformin increased AMPK signaling and showed a trend for blunted mTORC1 signaling increases in response to PRT.
Walton RG, Dungan CM, Long DE, et al. Aging Cell, 2019. PMID 31557380
2019 / Prospective, investigator-blinded, randomized controlled pilot study
In an investigator-blinded randomized controlled trial, healthy postmenopausal females with Fitzpatrick skin types 1 and 2 consumed 20% of their daily energy intake as either almonds or a calorie-matched snack for 16 weeks. Photographic analysis revealed that the almond group had significantly decreased wrinkle severity and width compared with the control group at 16 weeks (p < .02). Changes in skin barrier function, measured by transepidermal water loss, were nonsignificant between the groups relative to baseline at 16 weeks (p = .65), and no adverse effects were reported.
Foolad N, Vaughn AR, Rybak I, et al. Phytother Res, 2019. PMID 31576607
2018 / Randomized controlled trial
In a randomized controlled trial of 37 adults aged 60 to 75 years, consuming 24 g/day of freeze-dried blueberry for 90 days improved executive function markers compared to placebo. Participants receiving blueberry showed fewer verbal learning repetition errors (p = 0.031) and reduced switch cost on task switching (p = 0.033). However, the intervention produced no changes in gait or balance performance.
Miller MG, Hamilton DA, Joseph JA, et al. Eur J Nutr, 2018. PMID 28283823
2018 / Randomised crossover study
In a randomised crossover study, 119 older adults (healthy, with COPD, or with stable ischaemic heart disease) completed a 2-hour walk either along a busy commercial street (Oxford Street) or in an urban park (Hyde Park). Walking in Hyde Park increased lung function (FEV1 and FVC) and decreased pulse wave velocity and augmentation index up to 26 hours post-walk across all groups. Conversely, walking on Oxford Street attenuated these beneficial responses, and participants with COPD reported more sputum (OR 3.15, 95% CI 1.39-7.13) and wheeze (OR 4.00, 95% CI 1.52-10.50).
Sinharay R, Gong J, Barratt B, et al. Lancet, 2018. PMID 29221643
2018 / Double-blind, placebo-controlled randomized trial
Forty non-demented adults aged 51-84 were randomized to receive 90 mg curcumin twice daily as Theracurmin (N=21) or placebo (N=19) for 18 months. Curcumin improved verbal memory (SRT Consistent Long-Term Retrieval: ES=0.63, p=0.002; between-group ES=0.68, p=0.05), visual memory (BVMT-R Recall: ES=0.50, p=0.01; BVMT-R Delay: ES=0.51, p=0.006), and attention (ES=0.96, p<0.0001; between-group ES=0.67, p=0.04). FDDNP-PET binding decreased in the amygdala with curcumin (ES=-0.41, p=0.04; between-group ES=0.48, p=0.07) and remained unchanged in the hypothalamus with curcumin while increasing with placebo (between-group ES=0.55, p=0.02).
Small GW, Siddarth P, Li Z, et al. Am J Geriatr Psychiatry, 2018. PMID 29246725
2018 / Randomized clinical trial (2x2 factorial)
A 2x2 factorial randomized trial assigned 92 functionally limited older men for 6 months to controlled diets of 0.8 or 1.3 g/kg/d of protein, paired with weekly testosterone or placebo. Changes in lean body mass (0.31 kg; 95% CI, -0.46 to 1.08 kg; P = .43), appendicular lean mass, muscle strength, physical function, and well-being did not differ between protein levels, regardless of testosterone use. However, fat mass decreased significantly more with higher protein intake compared to the RDA group (difference, -1.12 kg; 95% CI, -2.04 to -0.21; P = .02).
Bhasin S, Apovian CM, Travison TG, et al. JAMA Intern Med, 2018. PMID 29532075
2018 / Randomized controlled trial
A randomized trial assigned 53 non-obese adults to either approximately 15% calorie restriction (n = 34) or a control group (n = 19) for two years. Participants in the restriction group lost an average of 8.7 kg, while control participants gained 1.8 kg. Measured daily energy expenditure was 80 to 120 kcal lower than predicted from weight loss, accompanied by decreased thyroid axis activity and lower F2-isoprostane levels.
Redman LM, Smith SR, Burton JH, et al. Cell Metab, 2018. PMID 29576535
2018 / 2 x 6-week randomized, double-blind, placebo-controlled crossover trial
In a 2 x 6-week randomized, double-blind, placebo-controlled crossover clinical trial, researchers assessed the effects of chronic supplementation with the NAD+ precursor nicotinamide riboside (NR) in healthy middle-aged and older adults. Chronic NR supplementation was well tolerated and effectively stimulated NAD+ metabolism. The results suggest that future clinical trials should further evaluate the potential benefits of NR for reducing blood pressure and arterial stiffness in this population.
Martens CR, Denman BA, Mazzo MR, et al. Nat Commun, 2018. PMID 29599478
2018 / Interventional crossover study
PET and 18F-florbetaben were used to measure brain β-amyloid burden (ABB) in 20 healthy controls after a night of rested sleep and after a night of sleep deprivation. One night of sleep deprivation significantly increased ABB in the right hippocampus and thalamus compared with baseline. These increases correlated with mood worsening after sleep deprivation but were not related to APOE genotype. Baseline ABB across subcortical regions and the precuneus was inversely associated with reported night sleep hours.
Shokri-Kojori E, Wang GJ, Wiers CE, et al. Proc Natl Acad Sci U S A, 2018. PMID 29632177
2018 / Multicentre pragmatic randomized controlled trial
A pragmatic randomized trial assigned 494 people with dementia to four months of supervised aerobic and strength exercise plus usual care (n=329) or usual care alone (n=165). At 12 months, the mean ADAS-cog score was 25.2 in the exercise group versus 23.8 in usual care (adjusted difference -1.4, 95% CI -2.6 to -0.2, P=0.03), indicating greater cognitive impairment in the exercise arm, though the clinical relevance is uncertain. No differences were detected in secondary outcomes, including activities of daily living, neuropsychiatric symptoms, or quality of life, despite improved six-minute walking distance in the exercise group (mean change 18.1 m, 95% CI 11.6 to 24.6 m).
Lamb SE, Sheehan B, Atherton N, et al. BMJ, 2018. PMID 29769247
2018 / Randomized, double-blind, placebo-controlled pilot trial
Thirty-nine participants with mild to moderate Alzheimer's disease were randomized to receive either an oral preparation containing 5 mg resveratrol, 5 g dextrose, and 5 g malate (RGM) or a matching placebo twice daily with grape juice for 1 year. At 12 months, change scores on the ADAS-cog, MMSE, ADCS-ADL, and NPI showed less deterioration in the treatment group than the control group, but none of these differences reached statistical significance. The intervention was found to be safe and well tolerated, with the most common adverse events being falls (all in the control group and deemed unrelated to the study).
Zhu CW, Grossman H, Neugroschl J, et al. Alzheimers Dement (N Y), 2018. PMID 30480082
2018 / Non-randomized exercise trial
A non-randomized trial compared 8 recreationally trained Nordic walkers and 9 experienced instructors performing 12-minute bouts of ordinary walking (OW) and Nordic walking (NW) as fast as possible. Significant group-by-walking type interactions were observed for distance/speed (P = 0.04), METs (P < 0.01), and heart rate (P = 0.04), showing higher values in instructors during NW versus OW. All pole force measures were significantly greater in instructors than recreational walkers (P <= 0.01). Increases in distance/speed and METs correlated significantly with peak pole force (r = 0.67 and r = 0.66) and pole impulse (r = 0.63 and r = 0.56).
Fujita E, Yakushi K, Takeda M, et al. PLoS One, 2018. PMID 30481199
2018 / Randomized controlled trial (sub-study)
This opportunistic sub-study within the Walnuts and Healthy Aging trial tested whether adding walnuts (15% of energy) for 2 years preserved leukocyte telomere length (LTL) compared to a habitual diet abstaining from walnuts. Adjusted mean LTL in controls was 7.360 kb at baseline and 7.061 kb at 2 years, compared to 7.064 kb at baseline and 7.074 kb at 2 years in the walnut group. The time-by-intervention interaction was nearly significant (p = 0.079), suggesting a trend toward preserved LTL. The authors note this exploratory finding should be confirmed in trials with adequate statistical power.
Freitas-Simoes TM, Cofán M, Blasco MA, et al. Nutrients, 2018. PMID 30518050
2017 / Double-blind, placebo-controlled trial
A double-blind, placebo-controlled trial examined the effects of 12 weeks of daily supplementation with 50 mg or 150 mg of a water-soluble CoQ10 (Q10Vital®) in 33 healthy subjects. Intake of CoQ10 limited seasonal deterioration of viscoelasticity, significantly reduced wrinkles and microrelief lines, and improved skin smoothness. No significant changes were observed in minimal erythema dose, skin hydration, or dermis thickness.
Žmitek K, Pogačnik T, Mervic L, et al. Biofactors, 2017. PMID 27548886
2017 / Randomized controlled trial
In a double-blind pilot study, 10 older adults with mild cognitive decline received an active grape formulation or placebo for six months. Participants taking the grape formulation maintained cerebral metabolism on FDG-PET scans, whereas the placebo group experienced significant metabolic declines in posterior cingulate and temporal regions (p < 0.05). Neuropsychological test scores did not differ significantly between groups.
Lee J, Torosyan N, Silverman DH Exp Gerontol, 2017. PMID 27856335
2017 / Randomized placebo-controlled trial
Eighty post-menopausal women aged 45-85 years were randomized to take trans-resveratrol or placebo for 14 weeks. Compared to placebo, resveratrol led to 17% increases in cerebrovascular responsiveness (CVR) to both hypercapnic (p = 0.010) and cognitive stimuli (p = 0.002). Resveratrol significantly improved performance in verbal memory tasks (p = 0.041) and overall cognitive performance (p = 0.020), which correlated with the increase in CVR (r = 0.327; p = 0.048). Mood tended to improve across multiple measures, but the changes were not statistically significant.
Evans HM, Howe PR, Wong RH Nutrients, 2017. PMID 28054939
2017 / Randomized controlled trial (retrospective subset analysis)
Banked CSF and plasma samples from a subset of 38 biomarker-confirmed Alzheimer's disease subjects randomized to resveratrol (up to 1 g orally twice daily) or placebo for 52 weeks were analyzed. At 52 weeks, resveratrol significantly reduced CSF MMP9 and increased MDC, IL-4, and FGF-2 compared to placebo, while increasing plasma MMP10 and decreasing IL-12P40, IL12P70, and RANTES from baseline. Resveratrol treatment attenuated declines in MMSE scores, ADCS-ADL scores, and CSF Aβ42 levels over 52 weeks, without altering tau levels.
Moussa C, Hebron M, Huang X, et al. J Neuroinflammation, 2017. PMID 28086917
2017 / Randomized controlled crossover trial
In a randomized trial involving 100 healthy participants, three monthly 5-day cycles of a fasting-mimicking diet reduced body weight, trunk fat, total body fat, blood pressure, and insulin-like growth factor 1. Crossover of the control group resulted in 71 participants finishing three cycles without serious adverse effects. A post hoc analysis revealed that improvements in blood pressure, fasting glucose, cholesterol, triglycerides, and C-reactive protein were greater in individuals initially at risk for disease.
Wei M, Brandhorst S, Shelehchi M, et al. Sci Transl Med, 2017. PMID 28202779
2017 / Randomized controlled trial
In a multicenter randomized controlled trial, 218 nonobese adults aged 21-51 years followed 25% calorie restriction or ad libitum eating for two years. The calorie restriction group achieved an 11.9% ± 0.7% energy reduction, lowering weight (-7.6 ± 0.3 vs 0.4 ± 0.5 kg), fat mass (-5.4 ± 0.3 vs 0.5 ± 0.4 kg), and fat-free mass (-2.0 ± 0.2 vs -0.0 ± 0.2 kg). Fat-free mass as a percentage of total body weight was higher in the calorie restriction group than controls.
Das SK, Roberts SB, Bhapkar MV, et al. Am J Clin Nutr, 2017. PMID 28228420
2017 / Randomized controlled trial
Healthy older adults were randomized to consume 30 mL of anthocyanin-rich blueberry concentrate (12 participants) or isoenergetic placebo (14 participants) over 12 weeks. Blueberry supplementation led to significant increases in brain activity relative to placebo within multiple regions including Brodmann areas 4/6/10/21/40/44/45, precuneus, anterior cingulate, and insula/thalamus (p < 0.001). Significant improvements in grey matter perfusion were observed in parietal (5.0 ± 1.8 vs -2.9 ± 2.4%, p = 0.013) and occipital (8.0 ± 2.6 vs -0.7 ± 3.2%, p = 0.031) lobes, alongside evidence suggesting improvement in working memory (p = 0.05).
Bowtell JL, Aboo-Bakkar Z, Conway ME, et al. Appl Physiol Nutr Metab, 2017. PMID 28249119